

## ENZC Starter Pack

OTC *Pink Current*

**Authorized Shares (A/S):** 3 Billion

**Outstanding Shares (O/S):** 2.797 Billion

**Insider Owned Shares:** 512 Million (22.4% of the O/S)

*Possible Dilution: most convertible debt has been exchanged for equity instruments that have a two-year conversion clause to postpone conversions for two years.*

*(Series C Preferred Shares)*

*\*Source: 2020 Year End Update*

### **Filings & Disclosure:**

<https://www.otcmartets.com/stock/ENZC/disclosure>

### **Highlights:**

#### Monoclonal Antibodies (mAbs)

- Clone 3 is non-toxic and has shown in initial in vitro testing to be effective against more than 95% of all strains and viral subtypes of HIV-1 against which it has been tested
- Seven additional conserved target sites (some with 98% conserved sequences) have now been identified, with the assistance of AI, against which fully human anti-HIV monoclonal antibodies will be produced in its lab. This allows the administration of a "cocktail" of antibodies, all targeting conserved and expectedly immutable sites
- Ongoing AI screening of 275,000 CoronaVirus isolates
- Patented proprietary methodology for producing fully human monoclonal antibodies (currently HIV & SARS CoV-2 & *expect more to come in the future*)

#### IPF / ITV (Immunotherapy Treatment)

- Inactivated Pepsin Fraction (IPF) is the active drug substance of ITV-1 and is a purified extract of porcine pepsin
- IPF/ITV has been successfully clinically tested and is pending the results of the ongoing toxicology study
- Free from major neurological, gastrointestinal and hematological side effects seen in the antiretrovirals in use today

#### **Potential Profits mAbs (From HIV only):**

- \$105 Billion in the first 11 years
- \*Source: <http://www.bioclonetics.com/profit-potential.html>
- \*Bioclonetics merged into Enzolytics Q4 2020

#### **Potential Profits (For IPF/ITV \*HIV only\*)**

- \$10 Million
- \*For Harry Zhabilov Patent US7479538
- \*Source: <https://enzolytics.com/patent>

### **Upcoming News & Catalysts:**

- Government Funding
  - Completion of SARS-CoV-2 mAbs
  - Patent approval of provisional patent for Multiple Sclerosis ( Ser. No. 62/123341 )
  - Harry Zhabilov Patents US8309072 & US8066982
    - Including claims for the treatment of:
      - Hepatitis
      - Herpes
      - Rheumatoid Arthritis
      - Autoimmune Diabetes
      - Anti-Tumor (In-Vivo)
      - Anti-Cancer (In-Vivo)
        - Specific Cancers Mentioned:
          - Kidney Cancer
          - Melanoma
          - Pancreatic Cancer
          - Non-Hodgkin's Lymphoma
          - Lung Carcinoma
          - Prostate Cancer
          - Spinal Cell Carcinoma
          - Soft Tissue Sarcoma or Fibrosarcoma
- To qualify to uplist to for OTCQB and eventually NASDAQ (PCAOB Audits In Process)
- Toxicity Results on ITV-1 from BTS Research
- Results from antibody studies at University of Strasbourg, France under direction of Dr. Christiane Moog, Ph.D, Research Director at INSERM
- Macaque trials @ CA National Primate Research Center (UC Davis)
- Updates RE: Antibody testing at San Raffaele Scientific Institute - Milan, Italy under direction of Dr. Gabriella Scarlatti, M.C., Ph.D., Head of Viral Evolution and Transmission Unit at SRSI
- Info RE: FDA recognition of studies in Bulgaria & steps to gain FDA approval thru reciprocity with EMA (European Medicines Agency) for IPF / ITV
- New Website

### **Misc Info:**

- *Artificial Intelligence* (AI) is being used to scan the hundreds of thousands of isolates that exist in 14 other prevalent viruses, ranging from influenza to Rabies to Ebola.
- It is expected that each of these viruses will eventually have their own monoclonal antibody lines
- Antibodies can be developed for **both human & animal** applications such as:
  - Asian and African Elephant Herpes
  - Primate Herpes
  - American Bison Brucellosis
  - Australian Koala HIV and Chlamydia
  - Feline Immunodeficiency Virus
  - African Lion Drug-Resistant Tuberculosis

### **Whos Who:**

Charles Cotropia - Chief Executive Officer

Juris Doctorate Degree Cornell Univ.,

B.S. Aerospace Engineering Univ. of Texas

Member of the Texas Bar Association

Licensed to practice before the United States Patent and Trademark Office

<https://www.linkedin.com/in/charles-s-cotropia-3059a25/>

Harry Zhabilov - Co-Chief Scientific Officer

Masters in Bulgaria at the University of Chemical Technology and Metallurgy in Sofia

Member of American Chemical Society

Member of American Institute of Chemical Engineers

<https://www.linkedin.com/in/harry-zhabilov-1a05571a/>

Joseph Cotropia MD - Co-Chief Scientific Officer

Doctor of Medicine Degree Univ. of Texas Southwestern Medical School

M.S. Physiological Chemistry

<https://www.linkedin.com/in/joseph-cotropia-md-bb5a879/>

Guarav Chandra MD, MBA - Chief Operating Officer

Doctor of Medicine Degree Kasturba Medical School Manipal

<https://www.linkedin.com/in/gaurav-chandra-md-mba-a8964b74/>

Ronald Moss - Medical Advisory Board

<https://www.linkedin.com/in/ronald-moss-18130212/>

### **Important Links:**

### Company Info

Enzolytics: <https://enzolytics.com/>

Bioclonetics (pre-merger): <http://www.bioclonetics.com/>

### Filings & Business Info

OTC Markets Profile: <https://www.otcmarkets.com/stock/ENZC/profile>

Delaware SOS: <https://icis.corp.delaware.gov/Ecorp/EntitySearch/NameSearch.aspx>

SEC EDGAR:

<https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001421851&owner=includ&count=40>

### Patents

US8309072B2: <https://patents.google.com/patent/US8309072B2>

US8066982B2: <https://patents.google.com/patent/US8066982B2>

US7479538: <https://patents.google.com/patent/US7479538>

### FDA NDIs

NDI 1083: <https://www.regulations.gov/searchResults?rpp=25&po=0&s=%22NDI%2B1083%22>

### Misc

[https://aumag.org/2013/09/26/the-future-of-clone-3/?fbclid=IwAR3OY2CE7AcA6-7mM9njlS6FtChPxy-7blJcPT\\_Z1vm5iQpODIEhzvYLSJU](https://aumag.org/2013/09/26/the-future-of-clone-3/?fbclid=IwAR3OY2CE7AcA6-7mM9njlS6FtChPxy-7blJcPT_Z1vm5iQpODIEhzvYLSJU)

### **Current Addresses:**

Enzolytics, Inc.

2000 North Central Expressway

Plano, TX 75074

Phone: (972)292-9414 Fax: (972)292-9414

Research Center

Enzolytics, Inc.

Texas A&M

College Station, TX

### **Link to the Share Tracker & Share Structure Analysis**

\*Publicly editable: Add your shares if you're holding long. Update as necessary.

[https://docs.google.com/spreadsheets/d/1HnxCYkqUz7LijvaIVdjob3lx6giuUJW\\_NwP3G4fawtl/e/dit?usp=sharing](https://docs.google.com/spreadsheets/d/1HnxCYkqUz7LijvaIVdjob3lx6giuUJW_NwP3G4fawtl/e/dit?usp=sharing)

### **Link to the Discord**

\*No pumping, no advertising, no hate speech or racial slurs

<https://discord.gg/ssVDPQ86>